Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T‐cell lymphoma

20 Aug 2008

Abstract excerpt

AIMS: Aberrant histone acetylation has been associated with malignancy and histone deacetylase (HDAC) inhibitors are currently being investigated in numerous clinical trials. So far, the malignancy most sensitive to HDAC inhibitors has been cutaneous T-cell lymphoma (CTCL). The reason for this sensitivity is unclear and studies on HDAC expression and histone acetylation in CTCL are lacking. The aim of this study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous lymphoproliferative disorders research
Share to Histone Deacetylase Inhibitors Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18671804
DOI: 10.1111/j.1365-2559.2008.03109.x

Provenance

PubMed metadata and Literature Corpus relationships.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T‐cell lymphomaPMID 18671804Read ↗

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphomaSemantic proximity Read ↗

Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell LymphomaSemantic proximity Read ↗

Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphomaSemantic proximity Read ↗

Genetic and epigenetic insights into cutaneous T-cell lymphomaSemantic proximity Read ↗

Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsSemantic proximity Read ↗

Epigenetics of Cutaneous T-Cell LymphomasSemantic proximity Read ↗

Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with ImmunotherapySemantic proximity Read ↗

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell LymphomaSemantic proximity Read ↗

Targeting histone deacetyalses in the treatment of B- and T-cell malignanciesSemantic proximity Read ↗

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applicationsSemantic proximity Read ↗

Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell LymphomaSemantic proximity Read ↗

Targeting histone deacetylases in T-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.